[go: up one dir, main page]

PE20020666A1 - DERIVADOS DE [1,2,4]TRIAZOLO[1,5-a]PIRIDINA COMO LIGANDOS DEL RECEPTOR DE ADENOSINA - Google Patents

DERIVADOS DE [1,2,4]TRIAZOLO[1,5-a]PIRIDINA COMO LIGANDOS DEL RECEPTOR DE ADENOSINA

Info

Publication number
PE20020666A1
PE20020666A1 PE2001001245A PE2001001245A PE20020666A1 PE 20020666 A1 PE20020666 A1 PE 20020666A1 PE 2001001245 A PE2001001245 A PE 2001001245A PE 2001001245 A PE2001001245 A PE 2001001245A PE 20020666 A1 PE20020666 A1 PE 20020666A1
Authority
PE
Peru
Prior art keywords
triazolo
aryl
alkyl
pyridine
pyridine derivatives
Prior art date
Application number
PE2001001245A
Other languages
English (en)
Inventor
Bernd Brodbeck
Matthias Heinrich Nettekoven
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020666A1 publication Critical patent/PE20020666A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A DERIVADOS DE [1,2,4]TRIAZOLO[1,5-a]PIRIDINA DE FORMULA I DONDE R1 ES ALCOXILO, CICLOALQUILO, NR'R'', ARILO; R' Y R" SON H, ALQUILO, ALQUENILO, ALQUINILO, (CR2)n-ARILO, (CH2)(n+1)NR2; (CH2)n-PIRIDINILO O JUNTO A N FORMAN PIRROLIDIN-1-IL, PIPERIDIN-1-IL, 3,4-DIHIDRO-1H-ISOQUINOLIN-2-IL, MORFOLINILO, ENTRE OTROS; R2 ES ARILO, HETEROARILO DE 5-6 MIEMBROS OPCIONALMENTE SUSTITUIDO POR ALQUILO, HALOGENO, HIDROXILO, ALCOXILO; X ES UN ENLACE, N(R)CH2; R ES H, ALQUILO; n ES 0-6; SON COMPUESTOS PREFERIDOS DIETILAMIDA DEL ACIDO 5-AMINO-2-(5-BROMO-FURAN-2-IL)[1,2,4]TRIAZOLO[1,5-a]PIRIDINA-7-CARBOXILICO; CICLOHEXIL-ETILAMIDA DEL ACIDO 5-AMINO-2-(5-METIL-TIOFEN-2-IL)-[1,2,4]TRIAZOLO[1,5-a]PIRIDINA-7-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS TIENE AFINIDAD POR EL RECEPTOR DE ADENOSINA A2a Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDAD DE PARKINSON, ALZHEIMER, NEUROPROTECCION, ESQUIZOFRENIA, ANSIEDAD, DOLOR, DEFICIT RESPIRATOPRIO, DEPRESION, ASMA, RESPUESTAS ALERGICAS, HIPOXIA, ISQUEMIA ATAQUES APOPLETICOS
PE2001001245A 2000-12-15 2001-12-12 DERIVADOS DE [1,2,4]TRIAZOLO[1,5-a]PIRIDINA COMO LIGANDOS DEL RECEPTOR DE ADENOSINA PE20020666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00127567 2000-12-15

Publications (1)

Publication Number Publication Date
PE20020666A1 true PE20020666A1 (es) 2002-07-27

Family

ID=8170683

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001245A PE20020666A1 (es) 2000-12-15 2001-12-12 DERIVADOS DE [1,2,4]TRIAZOLO[1,5-a]PIRIDINA COMO LIGANDOS DEL RECEPTOR DE ADENOSINA

Country Status (21)

Country Link
US (1) US6506772B1 (es)
EP (1) EP1347974B1 (es)
JP (1) JP4049672B2 (es)
KR (1) KR100540628B1 (es)
CN (1) CN1221551C (es)
AR (1) AR031799A1 (es)
AT (1) ATE281456T1 (es)
AU (2) AU3167402A (es)
BR (1) BR0116193A (es)
CA (1) CA2437006C (es)
DE (1) DE60106974T2 (es)
DK (1) DK1347974T3 (es)
ES (1) ES2230387T3 (es)
GT (1) GT200100253A (es)
MX (1) MXPA03005334A (es)
PA (1) PA8534701A1 (es)
PE (1) PE20020666A1 (es)
PT (1) PT1347974E (es)
UY (1) UY27074A1 (es)
WO (1) WO2002048145A1 (es)
ZA (1) ZA200304481B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030904A1 (en) * 2001-10-08 2003-04-17 F. Hoffmann-La Roche Ag 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
WO2004041285A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
WO2006020049A2 (en) 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2046788A1 (en) * 2006-07-12 2009-04-15 Syngeta Participations AG Triazolopyridine derivatives as herbicides
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
DK2429296T3 (en) * 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
US8815894B2 (en) * 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
KR20120034644A (ko) * 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
WO2013043520A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
JP7399589B2 (ja) * 2018-09-12 2023-12-18 日本化薬株式会社 有害生物防除剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356894A (en) 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
GB9226735D0 (en) 1992-12-22 1993-02-17 Ici Plc Azole derivatives
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives

Also Published As

Publication number Publication date
UY27074A1 (es) 2002-07-31
DE60106974D1 (de) 2004-12-09
EP1347974A1 (en) 2003-10-01
AU2002231674B2 (en) 2006-07-06
PA8534701A1 (es) 2002-08-26
KR100540628B1 (ko) 2006-01-11
DK1347974T3 (da) 2005-03-14
AU3167402A (en) 2002-06-24
WO2002048145A1 (en) 2002-06-20
ATE281456T1 (de) 2004-11-15
DE60106974T2 (de) 2005-11-03
ZA200304481B (en) 2004-09-09
ES2230387T3 (es) 2005-05-01
MXPA03005334A (es) 2004-04-02
CN1486314A (zh) 2004-03-31
EP1347974B1 (en) 2004-11-03
JP2004521096A (ja) 2004-07-15
CA2437006C (en) 2009-10-27
JP4049672B2 (ja) 2008-02-20
CA2437006A1 (en) 2002-06-20
BR0116193A (pt) 2003-09-23
US6506772B1 (en) 2003-01-14
CN1221551C (zh) 2005-10-05
KR20030061446A (ko) 2003-07-18
GT200100253A (es) 2002-07-31
AR031799A1 (es) 2003-10-01
PT1347974E (pt) 2005-02-28

Similar Documents

Publication Publication Date Title
PE20020666A1 (es) DERIVADOS DE [1,2,4]TRIAZOLO[1,5-a]PIRIDINA COMO LIGANDOS DEL RECEPTOR DE ADENOSINA
BRPI0407827B8 (pt) compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos
JP2019055954A (ja) 化学療法の間の正常細胞の一時的な保護
NO20075232L (no) Fremgangsmate for fremstilling av pyrido[2,3-d]pyrimidin-7-on og 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1 H)-on derivater
AR037680A1 (es) Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d
PE20030155A1 (es) Azaindoles como inhibidores de quinasas
PE20010629A1 (es) Derivados de triazolpiridinamina como ligandos de receptores de adenosina
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
AR015432A1 (es) Compuestos derivados de oxindol sustituidos, composiciones farmaceuticas, uso de dichos compuestos para la preparacion de medicamentos
AR031248A1 (es) Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos
SI2161273T1 (sl) Imidazo(4,5-c)piridin spojine in postopki protivirusnega zdravljenja
BR0314325A (pt) éteres aza-bicicloalquìlicos e seu uso como agonistas de alfa7-nachr
TR200401622T4 (tr) Pürin türevleri
ATE307132T1 (de) Purin derivate als a2b adenosin rezeptor antagonisten
AR035666A1 (es) Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
CR9092A (es) Metabolitos de ciertos derivados de [1,4]diazepino [6,7,1-ij]quinolina y metodos de preparacion y uso de los mismos
BR0315958A (pt) Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
UA93687C2 (en) N-(heteroaryl)-1-heteroarylalkyl-1h-indole-2-carboxamide derivatives, preparation and therapeutic use thereof
AR053540A1 (es) Derivados de pirrol e imidazol sustituidos,composiciones farmaceuticas que los contienen,y usos como agentes anticancerigenos
DE60100855D1 (de) 1,8-naphthalimid imidazo[4,5,1-de]acridone mit antitumorwirkung
DE3060897D1 (en) Sisomicin derivatives, process for their preparation and their use as medicines

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed